Join Aitia at the GAP-Net Site Optimization Conference in New Orleans
Join Aitia at the GAP-Net Site Optimization Conference in New Orleans, Louisiana on Feb 28 – March 1, 2024. This conference is exclusively focused on enhancing clinical trials, bringing together clinical research leaders and executive teams from prominent Alzheimer’s and Parkinson’s disease clinical trial sites across North America, along with pharmaceutical sponsors, CROs, and other […]
Prediction of HD-related clinical outcome progression and imaging markers using AI-based Digital Twins to be Presented at HDTC 2024
We are delighted to announce that Aitia will be at the upcoming 19th Annual Huntington’s Disease Therapeutics Conference being held from February 26-29 in Palm Springs, California. We will be presenting a poster focused on identification of gene pathways with direct causal relationships to Huntington’s Disease (HD) through Gemini Digital Twins of HD patients, based […]
Causal AI to learn “Gemini Digital Twins” for Drug Discovery and Clinical Development: Join our CMO, Bruce Church at AIRIS 2024
We are excited to announce that Aitia will be participating at the AI Regulatory & International Symposium 2024 conference in Seoul, Korea. Our Chief Mathematics Officer, Bruce Church, will be taking the stage in the New Medical Products and Treatment Opportunities Using AI session to talk about Aitia’s commitment in accelerating AI-driven discoveries and share […]
Unveiling the AI Dominance in Biopharma: STAT Post JPM Conference Insights
JPM conference has echoed discussions about AI across the biopharmaceutical landscape. Catch up on key insights shared in the latest STAT article titled: “At Health Care’s Biggest Investor Conference, AI’s High Hopes Collided with Skepticism.” Sanofi’s chief executive, Paul Hudson, revealed the widespread integration of AI within the company: “More than 11,000 people across the […]
Servier Will Apply Aitia’s Gemini Digital Twins to Parkinson’s Drug
Spotlight on our joint effort with Servier, strengthening our partnership by entering a new collaboration focused on neuroscience. The aim of this cooperation is to leverage Aitia’s Gemini Digital Twins to identify patients most likely to respond positively to Servier’s Leucine-Rich-Repeat-Kinase 2 inhibitor (LRRK2i) in development treatment for Parkinson’s disease. Read the full article on […]
Partner of Choice: Aitia and Servier Revolutionize the Landscape of Pancreatic Cancer Treatment
Spotlight on our joint effort with Servier to advance the discovery and simulation of drugs for Pancreatic Cancer. This strategic partnership aims to delve into the intricate mechanisms of this complex disease, with the goal of expediting the development of innovative therapies for individuals affected by pancreatic cancer. Read what Servier had to say about […]
Charles River and Aitia Join Forces to Harness AI and Gemini Digital Twins in Advancing Neurodegenerative and Oncology Research
Charles River Laboratories has entered into an agreement granting Aitia access to its artificial intelligence-powered drug solution platform. The objective is to expedite the development of multiple therapy programs targeting neurodegenerative diseases and oncology. Read more on the recent collaboration between Charles River and Aitia, in Fierce Biotech article. Full article available here.
Hear What Colin Hill had to say to Sidley on AI Use in Drug Discovery
Stephen Abreu, Sidley partner, talks to our Colin Hill about how the use of AI is revolutionizing the biotech space. Colin explains how our ability to predict and understand the actions of biological systems has historically been limited because of the complexity of “genetic circuitry,” but AI has allowed us to develop a more quantitative […]
Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023
We are delighted to announce that Aitia will be at the Clinical Trials on Alzheimer’s Disease conference (CTAD) being held from October 24-27 in Boston, MA. We will be presenting a poster focused on prediction of Amyloid PET positivity of Alzheimer’s Disease (AD) through Gemini Digital Twins of AD patients, based on blood-based biomarkers and […]
Leveraging AI in Healthcare and Life Sciences Discussion: Join our CEO, Colin Hill at the Sixth Annual International IP Summit
We are delighted to announce that Aitia will be participating in the Sixth Annual International IP Summit. Our CEO, Colin Hill, will be a featured speaker at an engaging discussion titled: Leveraging AI in Healthcare and Life Sciences: Key Legal Considerations. Colin will be joined by industry experts Dr. Bernardo Bizzo, the Senior Director of […]